Kikuo Isoda
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Kikuo Isoda has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
Fumitaka Ohsuzu
Internal Medicine I, National Defense Medical College, Tokorozawa, Japan
6 shared publicationsMasatoshi Kusuhara
‡Internal Medicine I and the **Second Department of Pathology, National Defense Medical College, Tokorozawa 359-8513, the ∥Center for Experimental Medicine, Institute of Medical Science, University of Tokyo, Tokyo 108-8639, and the ‡‡Laboratory of Chemistry, College of Liberal Arts and Sciences, Tokyo Medical and Dental University, Chiba 272-0827, Japan
5 shared publicationsTaizo Matsuki
‡Internal Medicine I and the **Second Department of Pathology, National Defense Medical College, Tokorozawa 359-8513, the ∥Center for Experimental Medicine, Institute of Medical Science, University of Tokyo, Tokyo 108-8639, and the ‡‡Laboratory of Chemistry, College of Liberal Arts and Sciences, Tokyo Medical and Dental University, Chiba 272-0827, Japan
3 shared publications- Yoichiro Iwakura
Graduate School of Agricultural and Life Sciences, The University of Tokyo, Tokyo, Japan
3 shared publications Kenichirou Nishikawa
From the First Department of Internal Medicine (K.I., M.S., N.I., K.N., M.K., F.O.), and Department of Physiology II (Y.N.), National Defense Medical College, Tokorozawa, Japan; and the Center for Experimental Medicine, Institute of Medical Science, University of Tokyo (T.M., R.H., Y.I.), Tokyo, Japan
2 shared publicationsKoji Miyazaki
‡Internal Medicine I and the **Second Department of Pathology, National Defense Medical College, Tokorozawa 359-8513, the ∥Center for Experimental Medicine, Institute of Medical Science, University of Tokyo, Tokyo 108-8639, and the ‡‡Laboratory of Chemistry, College of Liberal Arts and Sciences, Tokyo Medical and Dental University, Chiba 272-0827, Japan
2 shared publications
Latest Publications
- Open Access
- 1 January 2006
- Published by Japan Atherosclerosis Society in Journal of Atherosclerosis and Thrombosis
- Vol. 13 (1) , 21-30
The Effect of Interleukin-1 Receptor Antagonist on Arteries and Cholesterol Metabolism
Japan's largest platform for academic e-journals: J-STAGE is a full text database for reviewed academic papers published by Japanese societies
- 1 January 2006
- Published by Japan Atherosclerosis Society in Journal of Atherosclerosis and Thrombosis
- Vol. 13 (1) , 21-30
Open AccessThe Effect of Interleukin-1 Receptor Antagonist on Arteries and Cholesterol Metabolism
Japan's largest platform for academic e-journals: J-STAGE is a full text database for reviewed academic papers published by Japanese societies
- Open Access
- 1 February 2005
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 280 (8) , 7002-7009
Deficiency of Interleukin-1 Receptor Antagonist Deteriorates Fatty Liver and Cholesterol Metabolism in Hypercholesterolemic Mice
- 1 February 2005
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 280 (8) , 7002-7009
Open AccessDeficiency of Interleukin-1 Receptor Antagonist Deteriorates Fatty Liver and Cholesterol Metabolism in Hypercholesterolemic Mice
- Open Access
- 1 June 2004
- Published by Wolters Kluwer Health in Arteriosclerosis, Thrombosis, and Vascular Biology
- Vol. 24 (6) , 1068-1073
Lack of Interleukin-1 Receptor Antagonist Modulates Plaque Composition in Apolipoprotein E–Deficient Mice
Objective—Interleukin (IL)-1 plays an important role in atherosclerosis. IL-1 receptor antagonist (IL-1Ra) is an endogenous inhibitor of IL-1. However, the role of IL-1Ra in the development of atherosclerosis is poorly understood.Methods and Results—Mice that lacked IL-1Ra (IL-1Ra−/−) were crossed with apolipoprotein E-deficient (E−/−) mice and formation of atherosclerotic lesions was analyzed after 16 weeks or 32 weeks consumption of a normal chow diet. This study focused on the comparison of atherosclerotic lesion between IL-1Ra+/+/apoE−/− (n=12) and IL-1Ra+/−/apoE−/− mice (n=12), because of the significantly leaner phenotype in IL-1Ra−/−/apoE−/− mice compared with the others. Interestingly, atherosclerotic lesion size in IL-1Ra+/−/apoE−/− mice at age 16 weeks was significantly increased (30%) compared with IL-1Ra+/+/apoE−/− mice (PPPConclusions—These results suggest an important role of IL-1Ra in the suppression of lesion development during early atherogenesis and furthermore indicate its role in the modulation of plaque composition.
- 1 June 2004
- Published by Wolters Kluwer Health in Arteriosclerosis, Thrombosis, and Vascular Biology
- Vol. 24 (6) , 1068-1073
Open AccessLack of Interleukin-1 Receptor Antagonist Modulates Plaque Composition in Apolipoprotein E–Deficient Mice
Objective—Interleukin (IL)-1 plays an important role in atherosclerosis. IL-1 receptor antagonist (IL-1Ra) is an endogenous inhibitor of IL-1. However, the role of IL-1Ra in the development of atherosclerosis is poorly understood.Methods and Results—Mice that lacked IL-1Ra (IL-1Ra−/−) were crossed with apolipoprotein E-deficient (E−/−) mice and formation of atherosclerotic lesions was analyzed after 16 weeks or 32 weeks consumption of a normal chow diet. This study focused on the comparison of atherosclerotic lesion between IL-1Ra+/+/apoE−/− (n=12) and IL-1Ra+/−/apoE−/− mice (n=12), because of the significantly leaner phenotype in IL-1Ra−/−/apoE−/− mice compared with the others. Interestingly, atherosclerotic lesion size in IL-1Ra+/−/apoE−/− mice at age 16 weeks was significantly increased (30%) compared with IL-1Ra+/+/apoE−/− mice (PPPConclusions—These results suggest an important role of IL-1Ra in the suppression of lesion development during early atherogenesis and furthermore indicate its role in the modulation of plaque composition.
- 5 August 2003
- Published by Wolters Kluwer Health in Circulation
- Vol. 108 (5) , 516-518
Deficiency of Interleukin-1 Receptor Antagonist Promotes Neointimal Formation After Injury
Background— The cytokine interleukin (IL)-1 is an important mediator of inflammation and cardiovascular disease. Activity of this cytokine is modulated endogenously via the IL-1 receptor antagonist (IL-1Ra). The role of IL-1Ra in neointima formation after injury, however, is poorly understood. Methods and Results— Using IL-1Ra–deficient (IL-1Ra −/− ; backcrossed 8 generations into the C57BL/6J background) and wild-type (IL-1Ra +/+ ) mice, we investigated neointimal formation 3 weeks after femoral artery injury induced by an external vascular cuff model. Intima and media thicknesses were measured, and the intima/media ratio was calculated. The mean intimal thickness and the intima/media ratio of IL-1Ra −/− mice increased by 249% (31.8±2.9 μm [n=10] versus 9.1±0.7 μm [n=10]; P P +/+ mice. No significant differences were observed in the medial thickness. Control immunostaining for IL-1Ra in injured vessels localized IL-1β and the endogenous inhibitor in the endothelium and inflammatory cells of the adventitia in IL-1Ra +/+ but not IL-1Ra −/− mice. Conclusions— The absence of IL-1Ra promotes neointimal formation in mice after injury. These results suggest that endogenous IL-1Ra may suppress other occlusive vascular responses to injury, such as atherosclerosis and restenosis after angioplasty.
- 5 August 2003
- Published by Wolters Kluwer Health in Circulation
- Vol. 108 (5) , 516-518
Deficiency of Interleukin-1 Receptor Antagonist Promotes Neointimal Formation After Injury
Background— The cytokine interleukin (IL)-1 is an important mediator of inflammation and cardiovascular disease. Activity of this cytokine is modulated endogenously via the IL-1 receptor antagonist (IL-1Ra). The role of IL-1Ra in neointima formation after injury, however, is poorly understood. Methods and Results— Using IL-1Ra–deficient (IL-1Ra −/− ; backcrossed 8 generations into the C57BL/6J background) and wild-type (IL-1Ra +/+ ) mice, we investigated neointimal formation 3 weeks after femoral artery injury induced by an external vascular cuff model. Intima and media thicknesses were measured, and the intima/media ratio was calculated. The mean intimal thickness and the intima/media ratio of IL-1Ra −/− mice increased by 249% (31.8±2.9 μm [n=10] versus 9.1±0.7 μm [n=10]; P P +/+ mice. No significant differences were observed in the medial thickness. Control immunostaining for IL-1Ra in injured vessels localized IL-1β and the endogenous inhibitor in the endothelium and inflammatory cells of the adventitia in IL-1Ra +/+ but not IL-1Ra −/− mice. Conclusions— The absence of IL-1Ra promotes neointimal formation in mice after injury. These results suggest that endogenous IL-1Ra may suppress other occlusive vascular responses to injury, such as atherosclerosis and restenosis after angioplasty.
- 11 February 2003
- Published by Wolters Kluwer Health in Circulation
- Vol. 107 (5) , 679-681
Osteopontin Transgenic Mice Fed a High-Cholesterol Diet Develop Early Fatty-Streak Lesions
Background— Osteopontin (OPN) is a noncollagenous adhesion protein found at the site of atherosclerotic lesions. However, it has not yet been clarified whether or not OPN can promote atherosclerotic lesions. Methods and Results— We investigated the contribution of OPN to atherosclerosis by evaluating aortic sinus lesions of both OPN transgenic (Tg) and non-Tg mice fed an atherogenic diet (1.25% cholesterol) for 16 weeks. The atherosclerotic lesions were found to be significantly larger in OPN-Tg compared with those in non-Tg (17 859±2010 versus 6469±485 μm 2 , P P P Conclusions— The expression of OPN induces fatty-streak lesion formation in mice fed an atherogenic diet and inhibits IL-10 production by macrophages, thus suggesting that OPN plays an important role in the development of fatty-streak lesions in vivo.
- 11 February 2003
- Published by Wolters Kluwer Health in Circulation
- Vol. 107 (5) , 679-681
Osteopontin Transgenic Mice Fed a High-Cholesterol Diet Develop Early Fatty-Streak Lesions
Background— Osteopontin (OPN) is a noncollagenous adhesion protein found at the site of atherosclerotic lesions. However, it has not yet been clarified whether or not OPN can promote atherosclerotic lesions. Methods and Results— We investigated the contribution of OPN to atherosclerosis by evaluating aortic sinus lesions of both OPN transgenic (Tg) and non-Tg mice fed an atherogenic diet (1.25% cholesterol) for 16 weeks. The atherosclerotic lesions were found to be significantly larger in OPN-Tg compared with those in non-Tg (17 859±2010 versus 6469±485 μm 2 , P P P Conclusions— The expression of OPN induces fatty-streak lesion formation in mice fed an atherogenic diet and inhibits IL-10 production by macrophages, thus suggesting that OPN plays an important role in the development of fatty-streak lesions in vivo.
- 12 July 2002
- Published by Wolters Kluwer Health in Circulation Research
- Vol. 91 (1) , 77-82
Osteopontin Plays an Important Role in the Development of Medial Thickening and Neointimal Formation
Osteopontin (OPN) is a soluble secreted phosphoprotein that binds with high affinity to several integrins and it has been found at the site of atherosclerotic lesions. However, the role of OPN expression in vivo is still poorly understood. To investigate the physiological role of OPN in detail, we generated transgenic mice (Tg) overexpressing the OPN gene under control of the cytomegalovirus enhancer/chicken β-actin promoter. We detected OPN mRNAs in almost all tissues of 3 lines of Tg mice by Northern blotting. The serum levels of OPN were significantly higher in Tg than in non-Tg mice (782±107 versus 182±44 ng/mL; P P P P =0.022). The expression of OPN induces both medial thickening without injury and neointimal formation after injury, thus suggesting that OPN plays a role in the development of atherosclerosis, vascular remodeling, and restenosis after angioplasty in vivo.
- 12 July 2002
- Published by Wolters Kluwer Health in Circulation Research
- Vol. 91 (1) , 77-82
Osteopontin Plays an Important Role in the Development of Medial Thickening and Neointimal Formation
Osteopontin (OPN) is a soluble secreted phosphoprotein that binds with high affinity to several integrins and it has been found at the site of atherosclerotic lesions. However, the role of OPN expression in vivo is still poorly understood. To investigate the physiological role of OPN in detail, we generated transgenic mice (Tg) overexpressing the OPN gene under control of the cytomegalovirus enhancer/chicken β-actin promoter. We detected OPN mRNAs in almost all tissues of 3 lines of Tg mice by Northern blotting. The serum levels of OPN were significantly higher in Tg than in non-Tg mice (782±107 versus 182±44 ng/mL; P P P P =0.022). The expression of OPN induces both medial thickening without injury and neointimal formation after injury, thus suggesting that OPN plays a role in the development of atherosclerosis, vascular remodeling, and restenosis after angioplasty in vivo.